Natriuretic peptides: Prediction of cardiovascular disease in the general population and high risk populations

Disease Markers

Volumn 26, Issue 5-6, 2009, Pages 227-233

  Hildebrandt, Per ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Brain natriuretic peptide; Cardiovascular disease; General population; Heart failure; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DISEASE MARKER; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 70349902284     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/837256     Document Type: Review

References (41)

1. A. Gegenhuber, J. Struck, B. Dieplinger et al., Comparative evaluation of B-type natriuretic peptide, midregional pro- A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure, J Card Fail 13(1) (2007), 42-49.
2. J.P. Gøtze, Biochemistry of proBNP-derived peptides in plasma: the endocrine heart revisited, Clin Chem 50 (2004), 1503-1510.
3. F. Hartmann, M. Packer, A.J. Coats et al., Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial, Circulation 110 (2004), 178.
4. J.L. Januzzi, R. van Kimmenade, J. Lainchbury et al., NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study, Eur Heart J 27 (2006), 330-337.
5. S.K. James, B. Lindahl, A. Siegbahn et al., N-terminal probrain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. A Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV substudy, Circulation 108 (2003), 275-281.
6. C. Kragelund, B. Gronning, L. Kober et al., N-terminal pro- B-type natriuretic peptide and long-term mortality in stable coronary heart disease, N Engl J Med 352(7) (2005), 666-675. (Pubitemid 40239214)
7. K. Borch-Johnsen, B. Feldt-Rasmussen, S. Strandgaard et al., Urinary albumin excretion. An independent predictor of ischaemic heart disease, ArteriosclerThrombVasc Biol 19 (1999), 1992-1997.
8. M.H. Olsen, T.W. Hansen, M.K. Christensen et al., N-terminal pro-brain natriuretic peptide, but not high sensitivity Creactive protein, improves cardiovascular risk prediction in the general population, Eur Heart J 28(11) (2007), 1374-1381.
9. P.M. Ridker, C.H. Hennekens, J.E. Buring and N. Rifai, Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med 342(12) (2000), 836-843.
10. T.J. Wang, M.G. Larson, D. Levy et al., Plasma natriuretic peptide levels and the risk of cardiovascular events and death, N Engl J Med 350 (2004), 655-663. (Pubitemid 38364624)
11. R.S. Vasan, E.J. Benjamin, M.G. Larson et al., Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study, JAMA 288 (2002), 1252-1259. (Pubitemid 35001328)
12. C. Kistorp, I. Raymond, F. Pedersen et al., N-terminal probrain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults, JAMA 293 (2005), 1609-1616. (Pubitemid 40471791)
13. P.M. McKie, R.J. Rodeheffer, A. Cataliotti et al., Aminoterminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure, Hypertension 47 (2006), 874-880.
14. M.H. Olsen, T.W. Hansen, M.K. Christensen et al., New risk markers may change the HeartScore risk classification significantly in one-fifth of the population, J Hum Hypertension 23(2) (2009), 105-112.
15. M.H. Olsen, T.W. Hansen, M.K. Christensen et al., N-terminal pro-brain natriuretic peptide, but not high sensitivity Creactive protein, improves cardiovascular risk prediction in the general population, Eur Heart J 28 (2007), 1374-1381.
16. B. Zethelius, L. Berglund, J. Sundstrom et al., Use of multiple biomarkers to improve the prediction of death from cardiovascular causes, N Engl J Med 538(20) (2008), 2107-2116
17. S. Blankenberg, M.J. McQueen, M. Smieja et al., Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study, Circulation 114 (2006), 201-208.
18. J.R. Emberson, L.L. Ng, J. Armitage et al., N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study, J Am Coll Cardiol 49 (2007), 311-319.
19. T. Omland, M.S. Sabatine, K.A. Jablonski et al., Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial, J Am Coll Cardiol 50(3) (2007), 205-214.
20. M. Magnusson, O. Melander, B. Israelsson et al., Elevated plasma levels of NT-proBNP in patients with type 2 diabetes without overt cardiovascular disease, Diabetes Care 27(8) (2004), 1929-1935. (Pubitemid 38989234)
21. L. Tarnow, P. Hildebrandt, B.V. Hansen et al., Plasma Nterminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy, Diabetologia 48(2005), 149-155.
22. L. Tarnow, M.A. Gall, B.V. Hansen et al., Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes, Diabetologia 49(10) (2006), 2256-2262. (Pubitemid 44359085)
23. P. Gaede, P. Hildebrandt, G. Hess et al., Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria, Diabetologia 48 (2005), 156-163. (Pubitemid 40174668)
24. M. Huelsmann, S. Neuhold, G. Strunk et al., NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus, Eur Heart J 29(18) (2008), 2259-2264.
25. M.H. Olsen, K. Wachtell, O.W. Nielsen et al., N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy, J Hypertens 24 (2006), 1531-1539.
26. P. Hildebrandt and P.O. Collinson, Amino-Terminal Pro-B-Type Natriuretic Peptide Testing to Assist the Diagnostic Evaluation of Heart Failure in Symptomatic Primary Care Patients, Am J Cardiol 101(suppl) (2008), 25A-28A.
27. J.L. Januzzi, A.A. Chen-Tournoux and G. Moe, Amino-Terminal Pro-B-Type Natriuretic Peptide Testing for the Diagnosis or Exclusion of Heart Failure in Patients with Acute Symptoms, Am J Cardiol 101(suppl) (2008), 29A-38A.
28. K. Dickstein, A. Cohen-Solal, G. Filippatos et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008, Eur Heart J 29 (2008), 2388-2442.
29. I. Raymond, B.A. Groenning, P.R. Hildebrandt et al., The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population, Heart 89(7) (2003), 745-751.
30. L.C. Costello-Boerrigter, G. Boerrigter, M.M. Redfield et al., Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction, J Am Coll Cardiol 47(2006), 345-353. (Pubitemid 43063253)
31. G.S. Mak, A. DeMaria, P. Clopton et al., Utility of Bnatriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging recordings, Am Heart J 148(5) (2004), 895-902.
32. C. Tschope, M. Kasner, D. Westermann et al., The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements, Eur Heart J 26 (2005), 2277-2284.
33. B.A. Groenning, I. Raymond, P.R. Hildebrandt et al., Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population, Heart 90(3) (2004), 297-303.
34. O.W. Nielsen, T.A. McDonagh, S.D. Robb et al., Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population, J Am Coll Cardiol 41 (2003), 113-120. (Pubitemid 36044412)
35. K. Bibbins-Domingo, M. Ansari, N.B. Schiller et al., Is Btype natriuretic peptide a use-ful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the Heart and Soul Study, Am J Med 116(8) (2004), 509-516.
36. T. Omland, A. Aakvaag and H. Vik-Mo, Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment, Heart 76(3) (1996), 232-237.
37. A. Peer, G. Falkensammer, H. Alber et al., Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease, Heart 95(4) (2009), 297-303.
38. C. Kragelund, B. Groenning, T. Omland et al., Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease? Am Heart J 151 (2006), 712.e1-712.e7.
39. L. Amato, G. Paolisso, F. Cacciatore et al., Congestive heart failure predicts the development of non- insulindependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group, Diabetes Metab 23 (1997), 213-218.
40. M.H. Olsen, T.W. Hansen, M.K. Christensen et al., N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome, Hypertension 46 (2005), 660-666.
41. P. Hildebrandt, M. Boesen, M. Olsen et al., N-terminal pro brain natriuretic peptide in arterial hypertension - a marker or left ventricular dimensions and prognosis, Eur J Heart Fail 6 (2004), 313-317.